Aligos Therapeutics, Inc. (NASDAQ:ALGS) Short Interest Down 31.0% in October

Aligos Therapeutics, Inc. (NASDAQ:ALGS - Get Free Report) was the target of a large drop in short interest during the month of October. As of October 15th, there was short interest totalling 82,800 shares, a drop of 31.0% from the September 30th total of 120,000 shares. Approximately 3.7% of the shares of the company are sold short. Based on an average daily volume of 62,300 shares, the days-to-cover ratio is currently 1.3 days.

Aligos Therapeutics Price Performance

Aligos Therapeutics stock traded down $0.63 during mid-day trading on Friday, hitting $8.40. 201,203 shares of the company's stock traded hands, compared to its average volume of 35,139. The stock has a market cap of $656.12 million, a price-to-earnings ratio of -6.56 and a beta of 2.16. The firm has a 50 day simple moving average of $10.59 and a two-hundred day simple moving average of $13.44. Aligos Therapeutics has a fifty-two week low of $6.76 and a fifty-two week high of $30.00.

Aligos Therapeutics (NASDAQ:ALGS - Get Free Report) last posted its quarterly earnings data on Tuesday, August 6th. The company reported $0.75 earnings per share for the quarter, topping the consensus estimate of ($4.00) by $4.75. The firm had revenue of $1.06 million for the quarter. Aligos Therapeutics had a negative return on equity of 110.59% and a negative net margin of 1,100.48%. During the same quarter in the previous year, the business earned ($10.75) EPS. On average, research analysts anticipate that Aligos Therapeutics will post -8.2 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Separately, HC Wainwright reaffirmed a "buy" rating and set a $75.00 price target on shares of Aligos Therapeutics in a report on Wednesday.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in ALGS. Armistice Capital LLC increased its position in shares of Aligos Therapeutics by 5.3% in the second quarter. Armistice Capital LLC now owns 7,256,410 shares of the company's stock worth $2,540,000 after purchasing an additional 363,000 shares during the period. Opaleye Management Inc. increased its position in shares of Aligos Therapeutics by 25.7% in the first quarter. Opaleye Management Inc. now owns 1,630,000 shares of the company's stock worth $1,597,000 after purchasing an additional 333,000 shares during the period. Finally, Acadian Asset Management LLC increased its position in shares of Aligos Therapeutics by 26.1% in the second quarter. Acadian Asset Management LLC now owns 829,485 shares of the company's stock worth $289,000 after purchasing an additional 171,490 shares during the period. Institutional investors own 60.43% of the company's stock.

About Aligos Therapeutics

Aligos Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of novel therapeutics to address unmet medical needs in viral and liver diseases. Its drug candidate, ALG-055009, a small molecule THR-ß agonist that is in the Phase 2a clinical trial for the treatment of non-alcoholic steatohepatitis (NASH).